drugset / Trial / NCT00828711

Misoprostol Vaginal Insert (MVI) 100, 150, 200 mcg for Cervical Ripening and Induction of Labor

NCT00828711

Phase 2 Completed 374 enrolled Ferring Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the efficacy and safety of the 100, 150 and 200 mcg Misoprostol Vaginal Insert (MVI 100, MVI 150 and MVI 200) for women requiring cervical ripening and induction of labor.

Timeline

Start
2009-04
Primary completion
2009-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Misoprostol Other / unclassified 100 ug Other
Subject Misoprostol Other / unclassified 150 ug Other
Subject Misoprostol Other / unclassified 200 ug Other

Indications